SCHEMBL4012276

SCHEMBL4012276

CCCSc1nc(NC2CC2c2ccccc2)c2nnn([C@@H]3C[C@H](c4nnc[nH]4)[C@@H](O)[C@H]3O)c2n1

nearest known ligand 0.76

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ P2RY12 Q9H244 17/20 0.76
▸ PGR P06401 1/20 0.56
▸ ADORA3 P0DMS8 1/20 0.56
▸ CHRM1 P11229 1/20 0.56
▸ DRD1 P21728 1/20 0.56
▸ TBXA2R P21731 1/20 0.56
▸ PTGS1 P23219 1/20 0.56
▸ SLC6A2 P23975 1/20 0.56
▸ FPR3 P25089 1/20 0.56
▸ PDE4A P27815 1/20 0.56
▸ GPR183 P32249 1/20 0.56
▸ DRD3 P35462 1/20 0.56
▸ SLC6A3 Q01959 1/20 0.56
▸ KCNH2 Q12809 1/20 0.56
▸ PDE3A Q14432 1/20 0.56
▸ TMEM97 Q5BJF2 1/20 0.56
▸ SLC29A1 Q99808 1/20 0.56
▸ P2RY13 Q9BPV8 1/20 0.56
▸ CYP2C9 P11712 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13764359 1.00 P2RY12 (0.76) P2RY12PGRADORA3CHRM1DRD1
SCHEMBL4012773 0.88 P2RY12 (0.76) P2RY12PGRADORA3CHRM1DRD1
SCHEMBL4224154 0.88 P2RY12 (0.76) P2RY12PGRADORA3CHRM1DRD1
SCHEMBL13764358 0.88 P2RY12 (0.76) P2RY12PGRADORA3CHRM1DRD1
SCHEMBL4219168 0.88 P2RY12 (0.76) P2RY12PGRADORA3CHRM1DRD1
SCHEMBL4010212 0.88 P2RY12 (0.76) P2RY12PGRADORA3CHRM1DRD1
SCHEMBL4232361 0.88 P2RY12 (0.76) P2RY12PGRADORA3CHRM1DRD1
SCHEMBL4011841 0.88 P2RY12 (0.76) P2RY12PGRADORA3CHRM1DRD1
SCHEMBL4010214 0.88 P2RY12 (0.76) P2RY12PGRADORA3CHRM1DRD1
SCHEMBL7000932 0.87 P2RY12 (1.00) P2RY12PGRADORA3CHRM1DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2081433-A2 TRIAZOLOPYRIMIDINE DERIVATIVES AS ADP P2Y12 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2009-07-29 — — EP claimed
US-7566722-B2 Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists JANSSEN PHARMACEUTICA, N.V. (BE) 2009-07-28 — — US claimed
WO-2008054795-A2 TRIAZOLOPYRIMIDINE DERIVATIVES AS ADP P2Y12 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-05-08 — — WO claimed
US-20080108635-A1 Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists JANSSEN PHARMACEUTICA, N.V. (BE) 2008-05-08 — — US claimed
EP-2081433-A2 TRIAZOLOPYRIMIDINE DERIVATIVES AS ADP P2Y12 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2009-07-29 — — EP disclosed
US-7566722-B2 Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists JANSSEN PHARMACEUTICA, N.V. (BE) 2009-07-28 — — US disclosed
US-20080108635-A1 Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists JANSSEN PHARMACEUTICA, N.V. (BE) 2008-05-08 — — US disclosed
WO-2008054795-A2 TRIAZOLOPYRIMIDINE DERIVATIVES AS ADP P2Y12 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-05-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108635-A1 Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists P2RY12, P2RY1, P2RY2 P2RY12 1/4885PGR 394/4885ADORA3 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback